Harnessing AI For Drug Development – UK's BenevolentAI And MRCT Link

The hope artificial intelligence can revolutionize current drug discovery methods will be tested in a new collaboration between UK-based BenevolentAI and the medical research charity MRC Technology.

Ai
• Source: Shutterstock

The premise that artificial intelligence (AI) can help drug developers identify other uses for existing therapies – rather than making big outlays to find new ones - and also help to direct scientists to the most promising discoveries more quickly, lies behind a new collaboration between BenevolentAI and the UK life science medical research charity MRC Technology (MRCT).

BenevolentAI, which describes itself as the largest private AI company in Europe, has teamed up with MRCT to explore drug...

More from Strategy

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By 

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By 

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.

More from Business